Showing 341-350 of 5598 results for "".
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
https://reachmd.com/programs/cme/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/Tune in to explore age-related diagnostic considerations and confirmation strategies for generalized myasthenia gravis.Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/Dr. Jennifer Brown discusses CLL treatment sequencing after frontline failure, including resistance vs intolerance, MRD-guided strategies, and second-line therapy decisions.Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/Explore AML treatments targeting FLT3 and KMT2A/NPM1, focusing in on molecular diagnostics, clinical data, therapy sequencing, and adverse event management.Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
https://reachmd.com/programs/cme/navigating-upated-kdigo-clinical-practice-guideline-recommndations-to-maximize-proteinuria-reduction-in-patients-with-igan/26630/Explore updated KDIGO guideline recommendations and clinical strategies to reduce proteinuria in patients with IgA nephropathy.Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerInside the Decision: Case-Based Navigation of Brain Metastases in Breast and Lung Cancer
https://reachmd.com/programs/cme/inside-the-decision-case-based-navigation-of-brain-metastases-in-breast-and-lung-cancer/54766/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.The Prognostic Utility of Neurofilament Light Chain in Multiple Sclerosis: A Narrative Review
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/the-prognostic-utility-of-neurofilament-light-chain-in-multiple-sclerosis-a-narrative-review/32098/Neurofilament light chain has great promise as a prognostic biomarker in multiple sclerosis.